Last update 11/2023

| | | | Novelty | | | | Development Stage | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **AMR Accelerator Project** | **Asset Owner** | **Programme** | **New Class** | **New MoA** | **Mode of Action (MoA)** | **Description** | **Discovery** | **(Pre)-Hit to Lead** | **Lead to Candidate** | **Candidate to Phase I** | **Phase I** | **Phase 2a - alone or in combi-nation** | **Phase 2b - Dose ranging** | **Phase 2b - Regimen selection** | **Phase 2c - Duration rando-mization** |
| **GNA NOW €31 m** | NOSOPHARM | NOSO-502 | ✓ | ✓ | Inhibition bacterial ribosome | NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins, inhibiting the bacterial ribosome with a new mechanism of action. | | | ➡ | | | | | | |
| **TRIC-TB €8 m** | BioVersys and GSK | Alpibectir | ✓ | ✓ | Transcriptional modulator | Boosting Ethionamide efficacy and lowering the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections and define a new place for Ethionamide in 1st-line tuberculosis treatments. | | | | | | ➡* | | | |
| **AB-Direct €4 m** | GSK | Gepotidacin tissue distribution | ✓ | ✓ | Topoisomerase type II inhibitor | Demonstrating penetration of gepotidacin in tonsillar and prostate tissues. | | | | | ➡ | | | | |
| **ERA4TB €208 m** | | ERA4TB-01 | ✓ | ✓ | Cholesterol catabolism of mycobacteria | Molecule targeting cholesterol catabolism of mycobacteria. | | | | | ➡ | | | | |
| | | ERA4TB-02 | ✓ | ✓ | Mycobacterium tuberculosis tryptophan synthase | Compound targeting Mycobacterium tuberculosis tryptophan synthase, enzyme that catalyses the final two steps in the biosynthesis of tryptophan. | | | ➡ | | | | | | |
| | | ERA4TB-03 | | | Energy metabolism | Compounds targeting energy metabolism (electron chain transport). | | | | | ➡ | | | | |
| | | ERA4TB-04 | ✓ | ✓ | Lysine transfer RNA synthase | Compound targeting lysine transfer RNA synthase (Rv3598c), which is an essential gene as assessed by transposon mutagenesis. | | | ➡ | | | | | | |
| | | ERA4TB-06 | ✓ | ✓ | Mmpl3 | Mycobacterial membrane protein Large 3 (Mmpl3) compounds with potent in vitro inhibitory and bactericidal activity against Mycobacterium tuberculosis. | | | ➡ | | | | | | |
| | | ERA4TB-09 | ✓ | ✓ | Not known | Natural product analogs active against Mycobacterium tuberculosis. | | | ➡ | | | | | | |
| | | ERA4TB-10 | ✓ | ✓ | DprE1 | Piperazinobenzothiazinone derivative as anti-mycobacterial compound that targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1). | | | | | ➡ | | | | |
| **RespiriTB & NTM €10 m (TB) €8 m (NTM)** | JANSSEN | BC1 back up | ✓ | ✓ | BC1 | Lead optimisation programme on BC1 inhibitor. | | | ➡ | | | | | | |
| | | RespiriTB | ✓ | ✓ | Mycothiane reductase | Mycothione reductase target exploration. | ➡ | | | | | | | | |
| | | RespiriNTM | | | Not known | Progress novel assets (one First-in-human start) for Non-Tubercular Mycobacterium (NTM) that may act synergistically with Bedaquiline and cytochrome bc Drugs. | | ➡ | | | | | | | |
| **UNITE4TB €185 m** | GSK | GSK656 | ✓ | ✓ | LeuRS | A first-in-class investigational antitubercular agent which is being developed for the treatment of tuberculosis as part of a future combination regimen. New MoA/not regulatory approved product with this MoA. Suppresses protein synthesis in Mycobacterium tuberculosis (Mtb) by inhibiting the enzyme leucyl t-RNA synthetase (LeuRS). | | | | | | | | ➡ | |
| | Leibniz-HKI/ LMU | BTZ-043 | ✓ | ✓ | Cell wall synthesis | A first-in-class investigational antitubercular agent which is being developed for the treatment of tuberculosis as part of a future combination regimen. New MoA/not regulatory approved product with this MoA. BTZ-043 inhibits an enzyme (BTZ-043) with is essential for cell wall synthesis in mycobacteria tuberculosis. | | | | | | | ➡ | ➡ | |

## Accelerating scientific discoveries in the antimicrobial resistance (AMR) field

| | |
|---|---|
| **COMBINE €25 m** | Providing learnings derived from shared vaccine and/or antibacterial clinical trial data and improving understanding of variability and translatability of animal models of bacterial infection. |
| **PrIMAVeRa €9 m** | Developing a decision-making tool accessing health and economic outcomes of vaccines on the reduction of AMR. |

*This Phase 2a proof of concept trial is funded by the European & Developing Countries Clinical Trials Partnership and supported by the European Union.